Starling Oncology, Inc. (STLN)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue Quarterly

0 60M 120M 180M Q3 '21: 52.3M Q4 '21: 52.3M Q1 '22: 55.2M Q2 '22: 60.9M Q3 '22: 65M Q4 '22: 71.4M Q1 '23: 76.2M Q2 '23: 80.2M Q3 '23: 82M Q4 '23: 85.8M Q1 '24: 94.7M Q2 '24: 98.6M Q3 '24: 99.9M Q4 '24: 100.3M Q1 '25: 104.4M Q2 '25: 119.8M Q3 '25: 136.6M Q4 '25: 142M Q1 '26: 147.4M Q2 '26: 161.3M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Income Quarterly

-45M -30M -15M 0 15M 30M 45M Q3 '21: -2.2M Q4 '21: -40.8M Q1 '22: -18.5M Q2 '22: -18.3M Q3 '22: -20.1M Q4 '22: -25.1M Q1 '23: -32.9M Q2 '23: -14.9M Q3 '23: -13.9M Q4 '23: -15.3M Q1 '24: -18M Q2 '24: -16.4M Q3 '24: -13.9M Q4 '24: -11.9M Q1 '25: -9.9M Q2 '25: -11.2M Q3 '25: -8.1M Q4 '25: -6.9M Q1 '26: -6.5M Q2 '26: -4.6M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Net Income Quarterly

-30M -15M 0 15M 30M 45M Q3 '21: -3M Q4 '21: -10.2M Q1 '22: 19.3M Q2 '22: -5.5M Q3 '22: -2.7M Q4 '22: -11M Q1 '23: -30M Q2 '23: -16.9M Q3 '23: -17.4M Q4 '23: -18.8M Q1 '24: -19.9M Q2 '24: -15.5M Q3 '24: -16.1M Q4 '24: -13.2M Q1 '25: -19.6M Q2 '25: -17M Q3 '25: -16.5M Q4 '25: -7.5M Q1 '26: -2.5M Q2 '26: -9.8M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue Quarterly

Nothing in this filer's XBRL supports this figure for the periods asked for, so there is nothing to draw. That is a gap in the filing, not a zero.

Operating Cash Flow Quarterly

-24M -16M -8M 0 8M 16M 24M Q3 '21: -2.7M Q4 '21: -23.3M Q1 '22: -17M Q2 '22: -10.4M Q3 '22: -20.4M Q4 '22: -14M Q1 '23: -15.5M Q2 '23: -8.7M Q3 '23: -8.3M Q4 '23: -3.9M Q1 '24: -15.9M Q2 '24: -15.7M Q3 '24: 819K Q4 '24: 4M Q1 '25: -5M Q2 '25: -10.2M Q3 '25: -12.6M Q4 '25: 3.2M Q1 '26: -2.2M Q2 '26: 11.9M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow Quarterly

-27M -18M -9M 0 9M 18M 27M Q3 '21: -3.6M Q4 '21: -24.2M Q1 '22: -18M Q2 '22: -11.7M Q3 '22: -21.6M Q4 '22: -16M Q1 '23: -17.3M Q2 '23: -9.6M Q3 '23: -9.2M Q4 '23: -4.8M Q1 '24: -16.5M Q2 '24: -17.5M Q3 '24: 417K Q4 '24: 2.2M Q1 '25: -5.3M Q2 '25: -11.4M Q3 '25: -13.2M Q4 '25: 2.2M Q1 '26: -3.3M Q2 '26: 11M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 40M 80M 120M Q1 '21: 62.9M Q2 '21: 66M Q3 '21: 66M Q1 '22: 76.2M Q2 '22: 73M Q3 '22: 79.6M Q1 '23: 73.4M Q2 '23: 74.1M Q3 '23: 73.5M Q1 '24: 74.2M Q2 '24: 74.7M Q3 '24: 75.5M Q1 '25: 77.1M Q2 '25: 93.2M Q3 '25: 97.5M Q1 '26: 101.8M Q2 '26: 103M Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-1.05 -0.70 -0.35 0.00 0.35 0.70 1.05 Q4 '21: -0.17 Q1 '22: 0.06 Q2 '22: -0.05 Q3 '23: -0.89 Q4 '23: -0.92 Q1 '24: -0.81 Q2 '24: -0.79 Q3 '24: -0.78 Q4 '24: -0.72 Q1 '25: -0.71 Q2 '25: -0.69 Q3 '25: -0.65 Q4 '25: -0.55 Q1 '26: -0.36 Q2 '26: -0.29 Q4 '21 Q2 '22 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.